Advanced

Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma 63 patients with a minimum follow-up of 4 years

Smeland, Sigbjorn; Bruland, Oyvind S.; Hjorth, Lars LU ; Brosjo, Otte; Bjerkehagen, Bodil; Osterlundh, Gustaf; Jakobson, Ake; Hall, Kirsten Sundby; Monge, Odd R. and Bjork, Olle, et al. (2011) In Acta Orthopaedica 82(2). p.211-216
Abstract
Background and purpose The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from previous SSG trials and other osteosarcoma intergroup trials, and has been considered the best standard of care for patients with extremity localized, non-metastatic osteosarcoma. We analyzed the outcome in 63 consecutive patients. Patients and methods From 2001 through 2005, 63 patients recruited from centers in Sweden, Norway, and Finland were included. They received preoperative chemotherapy consisting of 2 cycles of paired methotrexate (12 g/m(2)), cisplatin (90 mg/m(2)), and doxorubicin (75 mg/m(2)). 3 cycles were administered post-operatively, and poor histological responders were given 3 additional cycles of ifosfamide (10-12 g/m(2))... (More)
Background and purpose The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from previous SSG trials and other osteosarcoma intergroup trials, and has been considered the best standard of care for patients with extremity localized, non-metastatic osteosarcoma. We analyzed the outcome in 63 consecutive patients. Patients and methods From 2001 through 2005, 63 patients recruited from centers in Sweden, Norway, and Finland were included. They received preoperative chemotherapy consisting of 2 cycles of paired methotrexate (12 g/m(2)), cisplatin (90 mg/m(2)), and doxorubicin (75 mg/m(2)). 3 cycles were administered post-operatively, and poor histological responders were given 3 additional cycles of ifosfamide (10-12 g/m(2)) as a salvage strategy. Results With a median follow-up of 77 months for survivors, the estimated metastasis-free and sarcoma-related survival at 5 years was 70% and 76%, respectively. 53 patients were treated with limb salvage surgery or rotationplasty and 2 patients experienced a local recurrence. 3 toxic deaths were recorded, all related to acute toxicity from chemotherapy. The 5-year metastasis-free survival of poor histological responders receiving add-on treatment with ifosfamide was 47%, as compared to 89% for good histological responders. Interpretation Outcome from the SSG XIV protocol compares favorably with the results of previous SSG trials and other published osteosarcoma trials. However, salvage therapy given to poor responders did not improve outcome to a similar degree as for good responders. In a multi-institutional setting, more than four-fifths of the patients were operated with limb salvage surgery or rotationplasty, with few local recurrences. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Orthopaedica
volume
82
issue
2
pages
211 - 216
publisher
Taylor & Francis
external identifiers
  • wos:000289170900015
  • scopus:79953806901
ISSN
1745-3682
DOI
10.3109/17453674.2011.566141
language
English
LU publication?
yes
id
5cbea7dd-a8e3-4f8d-8a68-9f034283df0a (old id 1918797)
date added to LUP
2011-05-02 10:47:27
date last changed
2017-08-27 05:02:51
@article{5cbea7dd-a8e3-4f8d-8a68-9f034283df0a,
  abstract     = {Background and purpose The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from previous SSG trials and other osteosarcoma intergroup trials, and has been considered the best standard of care for patients with extremity localized, non-metastatic osteosarcoma. We analyzed the outcome in 63 consecutive patients. Patients and methods From 2001 through 2005, 63 patients recruited from centers in Sweden, Norway, and Finland were included. They received preoperative chemotherapy consisting of 2 cycles of paired methotrexate (12 g/m(2)), cisplatin (90 mg/m(2)), and doxorubicin (75 mg/m(2)). 3 cycles were administered post-operatively, and poor histological responders were given 3 additional cycles of ifosfamide (10-12 g/m(2)) as a salvage strategy. Results With a median follow-up of 77 months for survivors, the estimated metastasis-free and sarcoma-related survival at 5 years was 70% and 76%, respectively. 53 patients were treated with limb salvage surgery or rotationplasty and 2 patients experienced a local recurrence. 3 toxic deaths were recorded, all related to acute toxicity from chemotherapy. The 5-year metastasis-free survival of poor histological responders receiving add-on treatment with ifosfamide was 47%, as compared to 89% for good histological responders. Interpretation Outcome from the SSG XIV protocol compares favorably with the results of previous SSG trials and other published osteosarcoma trials. However, salvage therapy given to poor responders did not improve outcome to a similar degree as for good responders. In a multi-institutional setting, more than four-fifths of the patients were operated with limb salvage surgery or rotationplasty, with few local recurrences.},
  author       = {Smeland, Sigbjorn and Bruland, Oyvind S. and Hjorth, Lars and Brosjo, Otte and Bjerkehagen, Bodil and Osterlundh, Gustaf and Jakobson, Ake and Hall, Kirsten Sundby and Monge, Odd R. and Bjork, Olle and Alvegård, Thor},
  issn         = {1745-3682},
  language     = {eng},
  number       = {2},
  pages        = {211--216},
  publisher    = {Taylor & Francis},
  series       = {Acta Orthopaedica},
  title        = {Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma 63 patients with a minimum follow-up of 4 years},
  url          = {http://dx.doi.org/10.3109/17453674.2011.566141},
  volume       = {82},
  year         = {2011},
}